tiprankstipranks
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
PremiumPress ReleasesWerewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
4M ago
Werewolf Therapeutics provides business update, highlights 2024 outlook
PremiumThe Fly
Werewolf Therapeutics provides business update, highlights 2024 outlook
4M ago
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
PremiumPress Releases
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
4M ago
Werewolf Therapeutics price target raised to $15 from $12 at Jefferies
PremiumThe FlyWerewolf Therapeutics price target raised to $15 from $12 at Jefferies
6M ago
Werewolf present preliminary data from Phase 1/1b trial for WTX-124
PremiumThe Fly
Werewolf present preliminary data from Phase 1/1b trial for WTX-124
6M ago
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
PremiumPress Releases
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100